Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-T for B Cell Malignancies
NCT03952923Phase 1Completed
- Sponsor
- Lu Daopei Hospital
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AVA-001 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Lu Daopei Hospital. Primary endpoints: Percentage of adverse events at 6 months and Objective Remission Rate at 6 months. Started Aug 2019; status: completed.
02
Drugs
AVA-001
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03952923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952923.